IMAC Holdings, Inc. provides services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company, through its subsidiary, Ignite Proteomics LLC (Ignite Proteomics), leverages its multi-analyte proteomic assay to help oncologists pinpoint the effective targeted therapies for each patient. Its product is a patented Reverse Phase Protein Array (RPPA) technology platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. Ignite Proteomics operates a CLIA-certified and CAP-accredited laboratory and offers single-gene tests by evaluating entire protein pathways in cancer cells. Its commercially available lab developed test (LDT), the Ignite RPPA Assay for Breast Cancer, is being utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.